Stockscreener 앱 받기
12.29
4.06%
0.48
시간 외 거래:
12.29
Generate Biomedicines Inc 주식(GENB)의 최신 뉴스
Generate Biomedicines (GENB) Stock Trends and Sentiment 2026 - MarketBeat
Flagship-backed Generate Bio seeks $425 million in US IPO - MSN
Book value per share of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView
Generate Biomedicines (GENB) 10K Form and SEC Filings 2026 - MarketBeat
Pretax income of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView
Generate Biomedicines, Inc. Income Statement – NASDAQ:GENB - TradingView
Tangible book value per share of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView
Cash from investing activities of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView
Generate Biomedicines, Inc. Cash Flow – NASDAQ:GENB - TradingView
Enterprise value to EBITDA ratio of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView
GENB News Today | Why did Generate Biomedicines stock go down today? - MarketBeat
Working capital per share of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView
Generate Biomedicines (GENB) Stock Price, News & Analysis - MarketBeat
Generate Biomedicines (NASDAQ:GENB) Upgraded by Wall Street Zen to "Hold" Rating - MarketBeat
Return on assets % of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView
Price to cash flow ratio of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView
Total common shares outstanding of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView
Generate Biomedicines (NASDAQ: GENB) holder reports 1.56M-share stake - Stock Titan
Fpn Ii, L.p. Net Worth (2026) - GuruFocus
Generate Biomedicines (GENB) Stock Chart and Price History 2026 - MarketBeat
Goodwin Advises Generate Biomedicines, Inc. On The Closing Of Its $400 Million Initial Public Offering - Mondaq
Latest GENB ETF News Today | Earnings, Events & Price Alerts - Intellectia AI
GENB Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
GENB Technical Analysis & Stock Price Forecast - Intellectia AI
Diluted net income available to common stockholders of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView
Dilution adjustment of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView
Generate Biomedicines (GENB) Valuation Check After Recent Share Price Weakness - Yahoo Finance
Generate Biomedicines Inc. (GENB) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Generate Biomedicines IPO Opens Nasdaq Chapter And Investor Watch Period - simplywall.st
Generate Biomedicines, Inc. Cash Flow – BOATS:GENB - TradingView
Diluted shares outstanding of Generate Biomedicines, Inc. – BOATS:GENB - TradingView
Generate Biomedicines, Inc. Earnings and Revenue – BOATS:GENB - TradingView
Generate Biomedicines, Inc. Statistics – BOATS:GENB - TradingView
Generate Biomedicines, Inc. Income Statement – BOATS:GENB - TradingView
Generate Biomedicines, Inc. Revenue Breakdown – BOATS:GENB - TradingView
Generate Biomedicines, Inc. (GENB) Stock Live Price, Chart & News - CoinCodex
GENB PE Ratio & Valuation, Is GENB Overvalued - Intellectia AI
GENB | Generate Biomedicines, Inc. Common Institutional Ownership - Quiver Quantitative
GENB | Generate Biomedicines, Inc. Common Insider Trading - Quiver Quantitative
Insider Buying: Jane Mendillo Acquires Shares in Generate Biomed - GuruFocus
GENB: Static price chart | Generate Biomedicines, Inc. | US3709201004 - marketscreener.com
Assessing Generate Biomedicines (GENB) Valuation After Recent Share Price Volatility - simplywall.st
Generate Biomedicines amends charter and bylaws ahead of Nasdaq IPO By Investing.com - Investing.com UK
Executive at Generate Biomedicines (GENB) awarded 190,034 stock options - Stock Titan
Generate Biomedicines (GENB) CEO adds options and IPO conversion shares - Stock Titan
Director at Generate Biomedicines (GENB) buys stock and receives 29,561 options - Stock Titan
Director at Generate Biomedicines (GENB) awarded 29,561-share stock option grant - Stock Titan
Generate Biomedicines amends charter and bylaws ahead of Nasdaq IPO - Investing.com
Flagship funds boost Generate Biomedicines (GENB) stake with IPO conversions, buys - Stock Titan
Governance revamp at Generate Biomedicines (NASDAQ: GENB) after IPO - Stock Titan
Generate Biomedicines, Inc.Common Stock (Nasdaq:GENB) Stock Quote - FinancialContent
Generate Biomedicines’ IPO Brings In $400M for Pivotal Tests of Severe Asthma Drug - Dealbreaker
Generate IPO raises $400 million but shares sink - The Pharma Letter
Generate Biomedicines (GENB) CMO awarded 42,230 stock options vesting over 4 years - Stock Titan
Generate Biomedicines, Inc.(NasdaqGS: GENB) added to NASDAQ Composite Index - marketscreener.com
EBITDA of GENERATE BIOMEDICINES INC – NASDAQ:GENB - TradingView
StockWatch: AI Drug Developer Generates $400M IPO - Genetic Engineering and Biotechnology News
Generate Biomedicines shares fall in weak Nasdaq debut for drug developer - WSAU
1.20%
0.06%
자본화:
|
볼륨(24시간):